SCHEMBL1332637

SCHEMBL1332637

O=C(O)COc1cc(F)c(F)cc1O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
TDP1 Q9NUW8 3/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GLA P06280 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTGDR2 Q9Y5Y4 7/20 0.41
PTGER2 P43116 1/20 0.41
FFAR1 O14842 1/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1332667 0.79 POLB (0.58) PKMPOLBSMN1; SMN2GLAL3MBTL1
SCHEMBL4576631 0.79 PKM (0.65) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL1332096 0.78 PKM (0.68) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL12667985 0.74 TDP1 (0.57) PKMTDP1L3MBTL1PTGDR2FFAR1
SCHEMBL8207221 0.73 TDP1 (0.51) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL13367355 0.72 PTGS2 (0.59) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL2949180 0.72 PKM (0.70) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL7963576 0.72 TDP1 (0.54) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL29757370 0.71 L3MBTL1 (0.61) PKMTDP1POLBSMN1; SMN2GLA
SCHEMBL257482 0.71 L3MBTL1 (0.61) PKMTDP1POLBSMN1; SMN2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394986-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (GB) 2013-03-12 US disclosed
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB 2011-11-17 US disclosed
US-8003703-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2011-08-23 US disclosed
EP-1660431-B1 PHENOXYACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2009-04-01 EP disclosed
US-20060293352-A1 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2006-12-28 US disclosed
EP-1660431-A2 PHENOXYACETIC ACID DERIVATIVES Astrazeneca AB (SE) 2006-05-31 EP disclosed
WO-2005018529-A2 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293352-A1 Phenoxiacetic acid derivatives HRH2, HRH1, HCAR2 PKM 1612/4885TDP1 4078/4885POLB 4073/4885
US-20110281898-A1 PHENOXIACETIC ACID DERIVATIVES HIF1A, HPD, HIF1AN PKM 544/4885TDP1 3242/4885POLB 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.